Immatics NV (IMTX)

[FACT-MASTER]

Noticed IMA402 was mentioned in the Q1 report and was initially focused on melanoma (similar to IMA203) Not sure when results will be coming out on IMA402, however from the article you posted, this trial could be well advanced. The announcement regarding the Oral Presentation at the Society for Melanoma Research Congress 2024 - October 11/24 only mentions IMA203. (https://finance.yahoo.com/news/immatics-announces-upcoming-oral-presentation-110000681.html)

I'll whisper this: Given that IMA203 received RMAT designation almost a year ago, i speculate that it is a distince possibility that FDA approval will be announced for IMA203 in and around the Melanoma Research Congress October 10-13/24 in New Orleans, Louisiana - just my opinion.



https://finance.yahoo.com/news/immatics-announces-first-quarter-2024-110000778.html

TCER® IMA402 (PRAME)

Immatics initiated the Phase 1/2 trial investigating the company’s fully owned TCER® candidate IMA402 in patients with recurrent and/or refractory solid tumors in August 2023 and the first patients have been dosed. Initial focus indications are ovarian cancer, lung cancer, uterine cancer and cutaneous and uveal melanoma, among others. IMA402 targets an HLA-A*02:01-presented peptide derived from the tumor antigen PRAME. This target peptide has been selected based on natural expression in native solid primary tumors and metastases at particularly high target density (peptide copy number per tumor cell identified by Immatics’ proprietary quantitative mass spectrometry engine XPRESIDENT®).

Immatics has recently engaged Patheon UK Limited, a subsidiary of ThermoFisher Scientific Inc., for the manufacturing of clinical IMA402 batches for its use within a potential registration-enabling trial. Patient recruitment and dose escalation continue to scale. First clinical data in at least 15 patients in dose escalation across multiple solid cancers, but initially focused on melanoma, is anticipated to be announced in 2H 2024.